A5030703994- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Immunodeficiency and Autoimmune Disorders
- Cancer therapeutics and mechanisms
- Immunotherapy and Immune Responses
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Chromatin Remodeling and Cancer
- Histone Deacetylase Inhibitors Research
- Synthesis and Biological Evaluation
- Blood groups and transfusion
- COVID-19 and healthcare impacts
- COVID-19 Impact on Reproduction
- Cancer Mechanisms and Therapy
- HIV/AIDS drug development and treatment
- Cancer Genomics and Diagnostics
- SARS-CoV-2 and COVID-19 Research
- Acute Myeloid Leukemia Research
- Ubiquitin and proteasome pathways
Icahn School of Medicine at Mount Sinai
2018-2025
Mount Sinai Medical Center
2018-2025
Mount Sinai Hospital
2024
Humanitas University
2023
Case Comprehensive Cancer Center
2023
Universität Hamburg
2023
Memorial Sloan Kettering Cancer Center
2023
University Medical Center Hamburg-Eppendorf
2023
Hackensack University Medical Center
2012-2022
Tisch Hospital
2018-2022
Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces accumulation activation tumor suppressor proteins, inhibits factor κB, reduces oncoprotein messenger RNA translation, is potential novel treatment for myeloma refractory to current therapeutic options.We administered oral selinexor (80 mg) plus dexamethasone (20 twice weekly patients with who had previous exposure bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, an alkylating...
Abstract BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all and their risk factors, evaluated the impact of infection prophylaxis patients treated with BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, two infection-related deaths during deep remissions. Most (84%) occurred disease The cumulative probability...
8006 Background: Linvoseltamab is a BCMA×CD3 bispecific antibody with encouraging efficacy and manageable safety profile in patients (pts) relapsed/refractory multiple myeloma (RRMM) (Bumma et al. ASH 2022). Two Phase (Ph) 2 full dose cohorts (50 mg 200 mg) the LINKER-MM1 (NCT03761108) trial were studied to optimize selection. Methods: Ph enrolled adults MM who progressed on/after ≥3 lines of therapy (LoT) including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 (Ab),...
PURPOSE We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg 200 doses linvoseltamab, B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS Phase II eligible patients had RRMM that either progressed on/after ≥three lines therapy including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 or was triple-class (PI/IMiD/anti-CD38) refractory. treatment once week through 14 then every 2...
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition translation oncoprotein mRNAs. We studied selinexor combination low-dose dexamethasone patients multiple myeloma refractory to most active available agents. Patients Methods This phase II trial evaluated 80 mg 20 mg, both orally twice weekly, bortezomib, carfilzomib,...
Abstract Background The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths the USA. Our institution treated 2000 patients during pandemic New York City. directly impacted cancer and organization of care. Mount Sinai Hospital a large diverse multiple myeloma (MM) population. Herein, we report characteristics infection serological response MM tertiary care York. Methods We performed retrospective study on cohort 58 with plasma-cell disorder (54 MM, 4 smoldering...
Abstract Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers the US and Europe. Thirty-one harbored t(11;14), 11 did not, one status was unknown. Patients received a venetoclax-containing regimen for at least 21- or 28-day cycle; median prior treatments three. The hematologic response rate all 68%; 63% achieved VGPR/CR....
Abstract Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, hyponatremia. We reviewed 437 patients multiple myeloma treated assessed kinetics adverse events impact supportive care measures. reduced both platelets neutrophils over first cycle...
B-cell maturation antigen (BCMA)-directed chimeric receptor T-cell (CAR T) therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma, and now there are two US Food Drug Administration-approved BCMA-directed CAR T products. However, despite high initial response rates, most eventually relapse. The outcomes of disease recurrence after have not been comprehensively studied, such an analysis would help define optimal treatment strategies. We analyzed the...
Integrative multiomics analysis of myeloma identifies 12 disease subtypes defined by specific patterns genetic alterations.
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but contribution pathogenic germline variants (PGV) in hereditary cancer genes to and outcomes is not well characterized. To address this, we analyzed exomes two independent cohorts 895 786 myeloma. PGVs were identified 8.6% Discovery cohort 11.5% Replication cohort, a notable presence high- or moderate-penetrance (associated autosomal dominant predisposition) DNA repair (3.6% 4.1%, respectively)....
Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, may therefore be particularly susceptible COVID-19. Here, we report outcomes risk factors for serious in patients treated at five large academic centers New York City spring of 2020, during which it was global epicenter SARS-CoV-2 pandemic. Of 100 (male 58%; median age 68) diagnosed COVID-19, 75 were admitted; these, 13 (17%) placed on invasive mechanical ventilation, 22 (29%)...
Abstract A Phase 2 dose-finding study evaluated isatuximab, an anti-CD38 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM; NCT01084252). Patients with ≥3 prior lines or refractory to both immunomodulatory drugs and proteasome inhibitors (dual refractory) were randomized isatuximab 3 mg/kg every weeks (Q2W), 10 Q2W(2 cycles)/Q4W, Q2W. fourth arm 20 QW(1 cycle)/Q2W. ( N = 97) had a median (range) age of 62 years (38–85), 5 (2–14) therapy lines, 85% double refractory. The...
T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), leading to the approval of 2 CAR products numerous BiAb trials. Data on outcomes after relapse following BiAbs are urgently required develop strategies for sequencing salvage therapies. We identified 58 progressing a trial at Mount Sinai Hospital. Progression-free survival (PFS)...